Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocritLipsic, E., Westenbrink, B. D., van der Meer, P., van der Harst, P., Voors, A. A., van Veldhuisen, D. J., Schoemaker, R. G. & van Gilst, W. H., Jan-2008, In : European Journal of Heart Failure. 10, 1, p. 22-29 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
Background: Erythropoietin (EPO) may improve cardiac function and induce neovascularisation in experimental models of chronic heart failure (CHF). However, the increased haematocrit associated with EPO treatment might exert concomitant deleterious effects.
Aim: To investigate the haematocrit independent effects of EPO on cardiac function.
Methods and results: Rats underwent permanent coronary artery ligation to induce myocardial infarction (MI) or sham surgery. Three weeks after MI, rats were randomly allocated to treatment with vehicle (MI) or the long-acting EPO analogue darbepoetin alfa administered in a high (40 mu g/kg/3 weeks, MI-EPO-high) or a low-dose (0.4 mu g/kg/3 weeks, MI-EPO-low). After 9 weeks, haemodynamic parameters, myocardial histology and Myosin Heavy Chain (MHC) isoforms were determined. High-dose EPO resulted in a significant increase in haematocrit (p
Conclusions: EPO improves cardiac function and induces neovascularisation at a dose that does not increase haematocrit, thereby circumventing the possible deleterious effects of increased erythropoiesis. (c) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
|Number of pages||8|
|Journal||European Journal of Heart Failure|
|Publication status||Published - Jan-2008|
- capillaries, heart failure, ventricular function, DOXORUBICIN-INDUCED CARDIOMYOPATHY, ISCHEMIA-REPERFUSION INJURY, ENDOTHELIAL PROGENITOR-CELL, ANALOG DARBEPOETIN-ALPHA, CHRONIC KIDNEY-DISEASE, MYOCARDIAL-INFARCTION, NEOVASCULARIZATION, ANEMIA, DYSFUNCTION, THERAPY